Organogenesis Holdings (ORGO) Asset Writedowns and Impairment (2018 - 2024)

Organogenesis Holdings' Asset Writedowns and Impairment history runs 6 years deep, the most recent figure standing at $18.8 million for Q2 2024.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $18.8 million in Q2 2024; TTM through Dec 2024 was $18.8 million, a 15544.26% increase from a year earlier, with the FY2024 full-year figure at $18.8 million, changed N/A from the prior year.
• Asset Writedowns and Impairment advanced to $18.8 million in Q2 2024 per ORGO's latest filing, from -$855000.0 in the prior quarter.
• Across five years, Asset Writedowns and Impairment topped out at $18.8 million in Q2 2024 and bottomed at -$1.4 million in Q4 2020.
• The 4-year median for Asset Writedowns and Impairment is $632000.0 (2021), against an average of $1.8 million.
• Biggest YoY gain for Asset Writedowns and Impairment was 2937.5% in 2020; the steepest drop was 613.43% in 2020.
• Year by year, Asset Writedowns and Impairment stood at -$1.4 million in 2020, then surged by 145.93% to $632000.0 in 2021, then slumped by 235.28% to -$855000.0 in 2022, then surged by 2303.74% to $18.8 million in 2024.
• Per Business Quant, the three latest ORGO Asset Writedowns and Impairment figures stand at $18.8 million (Q2 2024), -$855000.0 (Q4 2022), and $733000.0 (Q3 2022).